Chang A, Sohn R, Lu Z, Arbeit J, Lapi S. Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET. PLoS ONE. 2013;8:e58949 pubmed publisher

Kaempf S, Johnen S, Salz A, Weinberger A, Walter P, Thumann G. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci. 2008;49:3164-71 pubmed publisher

Elias P, Arbiser J, Brown B, Rossiter H, Man M, Cerimele F, et al. Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis. Am J Pathol. 2008;173:689-99 pubmed publisher

Lynn K, Udugamasooriya D, Roland C, Castrillon D, Kodadek T, Brekken R. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer. 2010;10:397 pubmed publisher

Aghi M, Rabkin S, Martuza R. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 2007;67:440-4 pubmed

Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low M, et al. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology. 2005;146:2952-62 pubmed